

**BB2170 Course in Drug Development – updated Feb 11<sup>th</sup>, 2011**

|                 |                     |                                                                                                                           |                                                         |
|-----------------|---------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Feb 11<br>15-17 | FB52<br>AlbaNova    | <i>L11. From Synthesis to Process:<br/>the Art of Transferring<br/>Laboratory Chemistry to Large<br/>Scale Production</i> | <i>Hans-Jürgen Federsel<br/>AstraZeneca / KTH</i>       |
| Feb 15<br>8-10  | FB52<br>AlbaNova    | <i>L12. Biopharmaceuticals</i>                                                                                            | <i>Andreas Castan<br/>Swedish Orphan Biovitrum</i>      |
| Feb 16<br>13-15 | FA32<br>AlbaNova    | <i>L13. Clinical Trials</i>                                                                                               | <i>An van Es-Johansson<br/>Swedish Orphan Biovitrum</i> |
| Feb 18<br>13-17 | FB55<br>AlbaNova    | <i>S1. Project presentations<br/>Group 1: Rheumatoid Arthritis</i>                                                        |                                                         |
| Feb 21<br>15-17 | FA32<br>AlbaNova    | <i>L14. Innovation Management in<br/>the Pharmaceutical Industry</i>                                                      | <i>Jonatan Freilich<br/>KTH</i>                         |
| Feb 22<br>10-12 | FB41<br>AlbaNova    | <i>L18. Commercialising Science<br/>Innovation and<br/>Entrepreneurship</i>                                               | <i>Eugen Steiner<br/>Health Cap</i>                     |
| Feb 22<br>15-17 | FB52<br>AlbaNova    | <i>L15. Pharmaceutical<br/>Formulation</i>                                                                                | <i>Thomas Österberg<br/>Pfizer</i>                      |
| Feb 24<br>13-15 | FA32<br>AlbaNova    | <i>L16. Intellectual Property<br/>Rights (IPR)</i>                                                                        | <i>Hampus Rystedt<br/>BRANN</i>                         |
| Feb 25<br>8-12  | FB55<br>AlbaNova    | <i>S2. Project presentations<br/>Group 2: Multiple sclerosis</i>                                                          |                                                         |
| Mar 1<br>10-12  | FB41<br>AlbaNova    | <i>L7. In vitro screening</i>                                                                                             | <i>Christin Andersson<br/>AstraZeneca</i>               |
| Mar 1<br>13-15  | FD5<br>AlbaNova     | <i>L17. Marketing and Media</i>                                                                                           | <i>Julian Stubbs</i>                                    |
| Mar 4<br>8-10   | FB53<br>AlbaNova    | <i>Reserve</i>                                                                                                            |                                                         |
| Mar 9<br>13-15  | FB53<br>AlbaNova    | <i>L10. Preclinical Development</i>                                                                                       | <i>Edis Travancic<br/>Swedish Orphan Biovitrum</i>      |
| Mar 15<br>14-18 | FB53, FB54,<br>FB55 | <i>Written exam</i>                                                                                                       |                                                         |